DBPR376-Targeting Small Molecule Mertansine Conjugate for Cancer Treatment(SMDC)
In order to address the impact of side effects on the quality of life of cancer patients during chemotherapy, a new generation of small molecule warhead-drug conjugate technology has been developed. National Health Research Institutes (NHRI) develop the peptide drug conjugate DBPR376 utilizes -Novel Luteinizing Hormone-Releasing Hormone Receptor (LHRH) as the targeting motif to detect signals released by cancer cells and allows accumulation that leads to the increasing cancer drug DM1 concentration in tumors.
法人
A deep learning-powered novel artificial intelligence algorithm and syste m to assist in the identification of pneumoperitoneum on abdominal com puted tomography
GLUT Targeting Small Molecule Drug Conjugation for Cancer Therapy
Ultrahigh-Sensitive Detection Platform Powered by Semiconductor-based Biosensor for the evaluation of Treatment on Acute Myeloid Leukemia
Novel Small Molecule AXL and MERTK Dual Tyrosine Kinase Inhibitor as A nti-Tumor and Immunomodulatory Agent
Technology maturity：Experiment stage
Exhibiting purpose：Technology transactions
Trading preferences：Exclusive license/assignment、New products development、Negotiate by self
Coming soon!